Attended by specialists in the digestive disease area, the 9th Chinese H. pylori and Digestive Diseases Forum was held in Guangzhou on August 8-9, 2014. This conference provided a platform for world and national leading experts in the digestive disease area to present research, exchange ideas and discuss collaborative opportunities. TenNor’s Founder and CEO, Dr. Zhenkun Ma was invited to speak at the Forum and presented a seminar titled “New Drugs for HP Eradication – Need and Reality.” The talk was well received. Professor Hu Fulian, Chairwoman of the conference commented: "This speech is one of the highlights of the Forum. It is totally consistent with the general theme of the conference: Cooperation, Exploration, Innovation and Truth-seeking." Vice President Erdong Hua and Investment Manager Xuepeng Guan from Frontline Bioventures attended this Forum.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com